Casino Night

Saturday, May 20, 2017
7:00-10:00 PM | $170 per person
Cocktail Attire Requested

Place your bets with the Foundation of the National Lipid Association and celebrate the 15th Anniversary of the NLA in style!

Enjoy a night of casino games, dinner, and dancing while doubling-down with fellow attendees. Gather together and reminisce on the past Presidents and the growth of the NLA over the previous 15 years.

Bring your friends, good luck charms, and dancing shoes!

Sponsorship tables are available
For info contact Chealsea Schroeder at the NLA office at cschroeder@lipidfoundation.org

Separate registration is required for this event

See registration page to purchase tickets.
Proceeds benefit the Foundation of the NLA.
New THIS YEAR

THURSDAY, MAY 18–SATURDAY, MAY 20
Step Challenge
Join the NLA’s inaugural Step Challenge to compete with your peers to take the most steps during your time in Philadelphia. See more on page 11.

THURSDAY, MAY 18–SATURDAY, MAY 20
Digital Poster Hall
Check out this year’s accepted abstracts in the newly added Digital Poster Hall, featuring large format, 47-inch flat panel monitors. See more on page 10.

SATURDAY, MAY 20 • 11:00–11:40 AM
W. Virgil Brown Distinguished Achievement Award & Lectureship
The NLA is proud to announce Robert H. Eckel, MD, FNLA, as the 2017 recipient of the W. Virgil Brown Distinguished Achievement Award. See more on page 2.

Register early and save at lipid.org/sessions

Table of CONTENTS

Featured Sessions ..................................................... 2
Schedule-at-a-Glance ........................................... 3
Agenda .............................................................................. 4
Program Planners ...................................................... 7
Scientific Meetings Committee ................................ 7
Program Faculty ............................................................ 8
Special Events ............................................................. 10
Pre-Conference Courses ........................................... 12
Program Overview .................................................. 13
Accreditation ............................................................... 14
Get Engaged ............................................................... 16
Venue & Travel Info ................................................... 16
Registration .................................................................. 17

Featured FACULTY

THURSDAY, MAY 18 • 5:10–5:30 PM
Daniel J. Rader, MD, FNLA
FUTURE: Non-LDL Related Mechanisms to ASCVD Risk Reduction

FRIDAY, MAY 19 • 3:20–3:45 PM
Brian A. Ference, MD, MPhil, MSc
Diabetes & PCSK9

FRIDAY, MAY 19 • 4:20–4:45 PM
G. Kees Hovingh, MD, PhD, MBA
Treatment & Developing Therapies in FH

FRIDAY, MAY 19 • 5:10–5:35 PM
Gerald F. Watts, MD, DSc, PhD
Outcome Data in FH Management: Where Do We Stand?
**Featured SESSIONS**

**Session IV: Familial Hypercholesterolemia Update on New Therapies**
**FRIDAY, MAY 19 | 4:15–6:00 PM**

G. Kees Hovingh, MD, PhD, MBA†
Samuel S. Gidding, MD, FNLA
Gerald F. Watts, MD, DSc, PhD

Familial hypercholesterolemia (FH) is a common hereditary cause of premature coronary heart disease. It has been estimated that 1 in every 250 people has FH and that less than 1% of patients with FH worldwide has been identified. If heterozygous familial hypercholesterolemia is left untreated, it is likely that CHD will manifest clinically prior to the age of 55 and half of all patients will prematurely die from the consequences of myocardial infarction. In recent years, several novel LDL-C lowering therapies have been developed and registered for patients with FH. In this interactive session, Drs. Samuel Gidding, Gerald Watts, and Kees Hovingh will provide an overview of the most recent data derived from pre-clinical lipid lowering studies.

**Session V: Trial Updates**
**SATURDAY, MAY 20 | 9:20–11:00 AM**

Christie M. Ballantyne, MD, FNLA†
Peter H. Jones, MD, FNLA
Harold E. Bays, MD, FNLA

PCSK9 inhibitors have shown great promise in regards to reductions in LDL-C and atherogenic lipoproteins. In 2017, we will have the first data in regards to the effects of PCSK9 inhibitors on cardiovascular events. The results of all completed studies will be reviewed at the annual meeting along with discussion of ongoing outcome trials. In addition, differences in trial design will be reviewed. These data will be extremely important in the discussion between provider and patients for the use of non-statin therapy when discussing the potential benefits, side effects, and cost in joint decision making.

**W. Virgil Brown Distinguished Achievement Award & Lectureship**
**SATURDAY, MAY 20 | 11:00–11:40 AM**

Robert H. Eckel, MD, FNLA

The NLA is proud to announce Robert H. Eckel, MD, FNLA, as the 2017 recipient of the W. Virgil Brown Distinguished Achievement Award. Dr. Eckel will also give the inaugural lecture associated with this award. This is the highest honor conferred by the NLA, and Dr. Eckel was selected for his outstanding contributions to the lipid community. The W. Virgil Brown Distinguished Achievement Award was established to honor one of the founding fathers of the NLA. Dr. Brown’s contributions to the field of lipidology and the National Lipid Association are unparalleled, and the Board of Directors of both the NLA and the Foundation of the NLA feel that this award should only be given to an exemplary clinician in the field of lipidology.
<table>
<thead>
<tr>
<th>WEDNESDAY MAY 17</th>
<th>THURSDAY MAY 18</th>
<th>FRIDAY MAY 19</th>
<th>SATURDAY MAY 20</th>
<th>SUNDAY MAY 21</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GENERAL</strong></td>
<td>Masters in Lipidology Registration 7:30–8:00 AM</td>
<td>Sessions Registration 12:30–6:00 PM</td>
<td>Sessions Registration 7:00 AM–5:00 PM</td>
<td>Sessions Registration 7:00 AM–11:30 AM</td>
</tr>
<tr>
<td></td>
<td>Lipid Academy Registration 8:00–8:30 AM</td>
<td>PLA &amp; SWLA Business Meeting 9:00–9:15 AM</td>
<td>MWLA &amp; SELA Business Meeting 9:00–9:15 AM</td>
<td>Breakfast 7:00–7:50 AM</td>
</tr>
<tr>
<td></td>
<td>Masters in Lipidology 8:30 AM–6:00 PM</td>
<td>Lipid Academy 8:00 AM–3:00 PM</td>
<td>NELA Business Meeting &amp; Young Investigator Awards 2:10–2:25 PM</td>
<td>2017–18 President’s Comments 7:50–8:00 AM</td>
</tr>
<tr>
<td></td>
<td>Lipid Academy 8:30 AM–5:15 PM</td>
<td>Town Hall 3:45–6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SESSIONS</strong></td>
<td>Masters in Lipidology 7:30 AM–3:30 PM</td>
<td>Session I 9:20–10:25 AM</td>
<td>Session V 9:20–11:00 AM</td>
<td>Session VIII 8:00–9:45 AM</td>
</tr>
<tr>
<td></td>
<td>Lipid Academy 8:00 AM–3:00 PM</td>
<td>Oral Poster Presentations 10:25–11:25 AM</td>
<td>W. Virgil Brown Distinguished Achievement Award &amp; Lectureship 11:00–11:40 AM</td>
<td>Session IX 9:45–11:30 AM</td>
</tr>
<tr>
<td></td>
<td>Town Hall 3:45–6:00 PM</td>
<td>Session II 12:25–2:10 PM</td>
<td>Session VI 1:05–2:50 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Session III 2:50–4:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Session IV 4:15–6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EXHIBIT &amp; POSTER HALL</strong></td>
<td>Welcome Reception &amp; New Member Reception 6:00–7:00 PM</td>
<td>Exhibit Hall Hours 7:00 AM–4:30 PM</td>
<td>Exhibit Hall Hours 7:00 AM–2:00 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lunch 11:25 AM–12:25 PM</td>
<td>Poster Hall Author Q&amp;A 8:00–9:00 AM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lunch &amp; Poster Hall Author Q&amp;A 12:05–1:05 PM</td>
<td></td>
</tr>
<tr>
<td><strong>SPECIAL EVENTS</strong></td>
<td>Dinner Symposium 7:00–9:00 PM</td>
<td>Breakfast Symposium 7:00–9:00 AM</td>
<td>Breakfast Symposium 7:00–9:00 AM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dinner Symposium 7:00–9:00 PM</td>
<td>Honors &amp; Awards Ceremony 5:30–7:00 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Foundation of the NLA Event 7:30–10:00 PM</td>
<td></td>
</tr>
</tbody>
</table>

**Memorial Wall**

While visiting the Digital Poster Hall, please stop by the Memorial Wall posthumously honoring past leaders and pioneers in the field of Lipidology.
### Agenda

**THURSDAY, MAY 18**

**Back to the Future: Clinical Experience with, and Access to, Lipid-Lowering Agents of the Past, Present, and Future, an NLA Town Hall**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:45–3:50 PM</td>
<td>President’s Welcome &amp; Introductions</td>
</tr>
<tr>
<td>3:50–4:00 PM</td>
<td>ARS Pre-Test</td>
</tr>
<tr>
<td>4:00–4:20 PM</td>
<td>PAST: Cholesterol, LDL-Lowering, and Statins</td>
</tr>
<tr>
<td></td>
<td>Joseph J. Saseen, PharmD, CLS, FNLA</td>
</tr>
<tr>
<td>4:20–4:35 PM</td>
<td>Audience Participation</td>
</tr>
<tr>
<td>4:35–4:55 PM</td>
<td>PRESENT: Treatments That Favorably Alter Lipid Metabolism</td>
</tr>
<tr>
<td></td>
<td>Dean A. Bramlet, MD, FNLA</td>
</tr>
<tr>
<td>4:55–5:10 PM</td>
<td>Audience Participation</td>
</tr>
<tr>
<td>5:10–5:30 PM</td>
<td>FUTURE: Non-LDL Related Mechanisms to ASCVD Risk Reduction</td>
</tr>
<tr>
<td></td>
<td>Daniel J. Rader, MD, FNLA</td>
</tr>
<tr>
<td>5:30–5:50 PM</td>
<td>Audience Participation</td>
</tr>
<tr>
<td>5:50–6:00 PM</td>
<td>ARS Post-Test</td>
</tr>
<tr>
<td>6:00–7:00 PM</td>
<td>WELCOME RECEPTION &amp; NEW MEMBER RECEPTION</td>
</tr>
<tr>
<td>7:00–9:00 PM</td>
<td>Dinner Symposium</td>
</tr>
</tbody>
</table>

**FRIDAY, MAY 19**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00–9:00 AM</td>
<td>Breakfast Symposium</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>EXHIBIT HALL OPENS</td>
</tr>
<tr>
<td>9:00–9:15 AM</td>
<td>PLA &amp; SWLA CHAPTER BUSINESS MEETINGS</td>
</tr>
<tr>
<td>9:15–9:20 AM</td>
<td>Morning Notes &amp; ARS Pre-Test</td>
</tr>
</tbody>
</table>

**Session I: Genetics & Genomics in Lipidology & Cardiovascular Risk Reduction**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:20–9:45 AM</td>
<td>Genetic Testing                                                         Nathan O. Stitziel, MD, PhD</td>
</tr>
<tr>
<td>9:45–10:10 AM</td>
<td>Genetic Scoring and Cardiovascular Risk                                 Sekar Kathiresan, MD</td>
</tr>
<tr>
<td>10:10–10:25 AM</td>
<td>Panel Session Q&amp;A, ARS Post-Test</td>
</tr>
<tr>
<td>10:25–11:25 AM</td>
<td>Oral Poster Presentations</td>
</tr>
<tr>
<td>11:25 AM–12:25 PM</td>
<td>LUNCH IN EXHIBIT HALL</td>
</tr>
</tbody>
</table>

**Session II: Familial Chylomicronemia Syndrome**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:25–12:30 PM</td>
<td>ARS Pre-Test</td>
</tr>
<tr>
<td>12:30–12:55 PM</td>
<td>Genetic Etiology of FCS                                                 Daniel J. Rader, MD, FNLA</td>
</tr>
<tr>
<td>12:55–1:20 PM</td>
<td>New Therapeutic Approaches to FCS                                      Richard L. Dunbar, MD</td>
</tr>
<tr>
<td>1:20–1:45 PM</td>
<td>Gene-Based Therapies for Familial Chylomicronemia Syndrome              Daniel Gaudet, MD, PhD</td>
</tr>
<tr>
<td>1:45–2:10 PM</td>
<td>Panel Session Q&amp;A, ARS Post-Test</td>
</tr>
<tr>
<td>2:10–2:25 PM</td>
<td>NELA CHAPTER BUSINESS MEETING &amp; YOUNG INVESTIGATOR AWARDS</td>
</tr>
</tbody>
</table>
### Agenda

#### Saturday, May 20

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00–9:00 AM</td>
<td><strong>CME/CE Breakfast Spotlight Symposium: Lipids, Inflammation, and Its Management from Atherogenesis to Atherothrombosis</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td><strong>EXHIBIT HALL OPENS</strong></td>
</tr>
<tr>
<td>8:00–9:00 AM</td>
<td><strong>Poster Hall Q&amp;A</strong></td>
</tr>
<tr>
<td>9:00–9:15 AM</td>
<td><strong>MWLA &amp; SELA Chapter Business Meetings</strong></td>
</tr>
<tr>
<td>9:15–9:20 AM</td>
<td><strong>Morning Notes &amp; ARS Pre-Test</strong></td>
</tr>
</tbody>
</table>

#### Session V: Trial Updates

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:20–9:45 AM</td>
<td><strong>PCSK9 Outcomes Studies</strong></td>
</tr>
<tr>
<td>9:45–10:10 AM</td>
<td><strong>CETP Outcomes Studies</strong></td>
</tr>
<tr>
<td>10:10–10:35 AM</td>
<td><strong>Lipid Altering Drugs in Development</strong></td>
</tr>
<tr>
<td>10:35–11:00 AM</td>
<td><strong>Panel Session Q&amp;A, ARS Post-Test</strong></td>
</tr>
<tr>
<td>11:00–11:40 AM</td>
<td><strong>W. Virgil Brown Distinguished Achievement Award &amp; Lectureship</strong></td>
</tr>
<tr>
<td>11:40 AM–12:05 PM</td>
<td><strong>NLA &amp; FOUNDATION BUSINESS MEETING</strong></td>
</tr>
<tr>
<td>12:05–1:05 PM</td>
<td><strong>LUNCH IN EXHIBIT HALL &amp; POSTER HALL Q&amp;A SESSION</strong></td>
</tr>
</tbody>
</table>

#### Session VI: Role of Non-Invasive Imaging in Risk Stratification & Treatment of ASCVD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:05–110 PM</td>
<td><strong>ARS Pre-Test</strong></td>
</tr>
</tbody>
</table>

#### Session III: New Information for PCSK9 Inhibition

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:25–2:50 PM</td>
<td><strong>BREAK IN EXHIBIT HALL</strong></td>
</tr>
<tr>
<td>2:50–2:55 PM</td>
<td><strong>ARS Pre-Test</strong></td>
</tr>
<tr>
<td>2:55–3:20 PM</td>
<td><strong>Role of Diet &amp; Exercise &amp; the Impact on Lipids &amp; PCSK9</strong></td>
</tr>
<tr>
<td>3:20–3:45 PM</td>
<td><strong>Diabetes &amp; PCSK9</strong></td>
</tr>
<tr>
<td>3:45–4:00 PM</td>
<td><strong>Panel Session Q&amp;A, ARS Post-Test</strong></td>
</tr>
<tr>
<td>4:00–4:15 PM</td>
<td><strong>BREAK</strong></td>
</tr>
</tbody>
</table>

#### Session IV: Familial Hypercholesterolemia Update on New Therapies

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:15–4:20 PM</td>
<td><strong>ARS Pre-Test</strong></td>
</tr>
<tr>
<td>4:20–4:45 PM</td>
<td><strong>Treatment &amp; Developing Therapies in FH</strong></td>
</tr>
<tr>
<td>4:45–5:10 PM</td>
<td><strong>FH in Children – Then &amp; Now</strong></td>
</tr>
<tr>
<td>5:10–5:35 PM</td>
<td><strong>Outcome Data in FH Management: Where Do We Stand?</strong></td>
</tr>
<tr>
<td>5:35–6:00 PM</td>
<td><strong>Panel Session Q&amp;A, ARS Post-Test</strong></td>
</tr>
<tr>
<td>7:00–9:00 PM</td>
<td><strong>Dinner Symposium</strong></td>
</tr>
</tbody>
</table>
## Agenda

**11:10–1:35 PM**  
Coronary Artery Calcium – Refining Risk Estimates & Defining Treatment  
Michael J. Blaha, MD, MPH

**1:35–2:00 PM**  
Coronary CT Angiography – Advanced Plaque Imaging & Beyond  
Michael D. Shapiro, DO, FNLA*

**2:00–2:25 PM**  
Update from the FH CTA Consortium  
Eric J.G. Sijbrands, MD, PhD

**2:25–2:50 PM**  
Panel Session Q&A, ARS Post-Test

**2:50–3:20 PM**  
Break

### Session VII: Less Common Lipid Disorders

**3:20–3:25 PM**  
ARS Pre-Test

**3:25–3:50 PM**  
Familial Dysbetalipoproteinemia  
Paul N. Hopkins, MD, MSPH, FNLA*

**3:50–4:15 PM**  
Sitosterolemia  
Joyce L. Ross, MSN, ANP, CRNP, CLS, FNLA

**4:15–4:40 PM**  
The Perplexing Exception of Lipoprotein-X Disease  
Laurence S. Sperling, MD

**4:40–5:05 PM**  
Panel Session Q&A, ARS Post-Test

**5:30–7:00 PM**  
Honors & Awards Ceremony  
(See more information on page 11)

**7:30–10:00 PM**  
Foundation of the NLA Event  
(See more information on page 11)

### SUNDAY, MAY 21

**7:00–7:50 AM**  
Breakfast

**7:50–8:00 AM**  
2017–2018 President Comments & Morning Notes

### Session VIII: Updates in Lipid Therapeutics 2017

**8:00–8:05 AM**  
ARS Pre-Test

**8:05–8:30 AM**  
Lipid Trials in the Last 12 Months  
Kevin C. Maki, PhD, CLS, FNLA

**8:30–8:55 AM**  
NLA Annual Summary Update  
Harold E. Bays, MD, FNLA*

**8:55–9:20 AM**  
NLA Annual Summary Update – Appendix, Tables, & Social Media  
James A. Underberg, MD, MS, FNLA*

**9:20–9:45 AM**  
Panel Session Q&A, ARS Post-Test

### Session IX: The Role of Social Media in Practice

**9:45–9:50 AM**  
ARS Pre-Test

**9:50–10:15 AM**  
Role of Social Media in Clinical Trial Recruitment  
Marie F. Ennis-O’Connor

**10:15–10:40 AM**  
Role of Social Media in Medical Publishing & Sharing New Research  
Katey Rayner, PhD

**10:40–11:05 AM**  
Role of Social Media in Patient Education  
Martha Gulati, MD, MS

**11:05–11:30 AM**  
Panel Session Q&A, ARS Post-Test

---

*DIPLOMATE, AMERICAN BOARD OF CLINICAL LIPIDOLOGY

The NLA invites speakers and guests to provide scientific medical opinion, which do not necessarily reflect the policy of the NLA. The schedule and faculty are subject to change.
The NLA invites speakers and guests to provide scientific medical opinion, which do not necessarily reflect the policy of the NLA.

The schedule and faculty are subject to change.
Program FACULTY

Benoit J. Arsenault, PhD
Assistant Professor
Faculty of Medicine
Laval University
Québec, Canada

Harold E. Bays, MD, FNLA*
Medical Director/President
Louisville Metabolic and Atherosclerosis Research Center
Louisville, KY

Michael J. Blaha, MD, MPH
Director of Clinical Research
Johns Hopkins Ciccarone Center for the Prevention of Heart Disease
Baltimore, MD

Dean A. Bramlet, MD, FNLA*
Assistant Consulting Professor of Medicine
Duke University
Medical Director, Cardiovascular Diagnostic Center
The Heart & Lipid Institute of Florida
St. Petersburg, FL

Richard L. Dunbar, MD
Assistant Professor of Medicine
Department of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Robert H. Eckel, MD, FNLA*
Professor of Medicine
Professor of Physiology and Biophysics
Charles A. Boettcher II Chair in Atherosclerosis
University of Colorado
Anschutz Medical Campus
Aurora, CO

Marie F. Ennis-O’Connor
Board of Trustees
Patient Empowerment Foundation
Dublin, Ireland

Brian A. Ference, MD, MPhil, MSc
Associate Professor of Medicine
Clinical Chief, Division of Cardiovascular Medicine
Director, Cardiovascular Genomic Research Center
Wayne State University School of Medicine
Detroit, MI

Daniel Gaudet, MD, PhD
Associate Professor of Medicine
Université de Montréal Scientific Director and Strategic Development Officer
BioBank, Genome
Chicoutimi, Quebec, Canada

Samuel S. Gidding, MD, FNLA
Cardiology Division Head
Nemours Cardiac Center
Professor of Pediatrics
Sidney Kimmel Medical College
Haddonfield, NJ

Martha Gulati, MD, MS
Chief of Cardiology, University of Arizona
Editor in Chief – CardioSmart
Phoenix, AZ

Paul N. Hopkins, MD, MSPH, FNLA*
Professor of Internal Medicine
Cardiovascular Genetics
University of Utah Health Care
Salt Lake City, UT

*DIPLOMATE, AMERICAN BOARD OF CLINICAL LIPIDOLOGY

The NLA invites speakers and guests to provide scientific medical opinion, which do not necessarily reflect the policy of the NLA. The schedule and faculty are subject to change.
Joseph J. Saseen, PharmD, CLS, FNLA
Professor
Clinical Pharmacy and Family Medicine
University of Colorado Denver
Anschutz Medical Campus
Aurora, CO

Michael D. Shapiro, DO, FNLA*
Associate Professor of Medicine and Radiology
Director, Cardiac MR CT Program
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, OR

G. Kees Hovingh, MD, PhD, MBA
Department of Vascular Medicine
Academic Medical Center
Amsterdam, The Netherlands

Eric J.G. Sijbrands, MD, PhD
Professor, Internal Medicine
Erasmus MC, Rotterdam
Head, Pharmacology, Vascular and Metabolic Disease Section
Head, Vascular Genetics Unit
Department of Internal Medicine
Rotterdam, The Netherlands

Peter H. Jones, MD, FNLA*
Associate Professor of Medicine
Co-Director
Lipid Metabolism and Atherosclerosis Clinic
Center for Cardiovascular Disease Prevention
Houston Methodist DeBakey Heart and Vascular Center
Baylor College of Medicine
Houston, TX

Laurence S. Sperling, MD
Professor of Medicine (Cardiology)
Director, Emory Heart Disease Prevention Center
Professor of Global Health
Hubert Department of Global Health
Rollins School of Public Health
Emory University
Atlanta, GA

Sekar Kathiresan, MD
Director, Center for Human Genetic Research
Massachusetts General Hospital
Boston, MA

Nathan O. Stitziel, MD, PhD
Assistant Professor of Medicine and Genetics
Washington University School of Medicine
Saint Louis, MO

Kevin C. Maki, PhD, CLS, FNLA
Chief Science Officer
Midwest Center for Metabolic & Cardiovascular Research
Chicago, IL

Gerald F. Watts, MD, DSc, PhD
Winthrop Professor
Cardiometabolic Medicine
University of Western Australia
Perth, Australia

Katey Rayner, PhD
Assistant Professor
Director, Cardiometabolic microRNA Laboratory
University of Ottawa Heart Institute
Ottawa, Ontario, Canada

*DIPLOMATE, AMERICAN BOARD OF CLINICAL LIPIDOLOGY

The NLA invites speakers and guests to provide scientific medical opinion, which do not necessarily reflect the policy of the NLA.
The schedule and faculty are subject to change.
Special EVENTS

WELCOME RECEPTION & NEW MEMBER RECEPTION

THURSDAY, MAY 18 • 6:00–7:00 PM
Join your fellow colleagues and the exhibitors for an opening reception on Thursday evening in the Exhibit Hall. Visit with more than 40 exhibiting companies and mingle, while enjoying tasty hors d’oeuvres and cocktails.

ARE YOU A NEW MEMBER?
The New Member Reception — which is taking place during the Welcome Reception in the Exhibit Hall — is a wonderful opportunity to mingle with leaders in the organization and ask them any questions you may have about their experience. Enjoy cocktails and light hors d’oeuvres with new and active members in the organization. Most importantly, this reception gives you the opportunity to create new connections with other members that will enrich your experience as an NLA member and last a lifetime!

These receptions are included in the attendee registration fee. Guests are welcome to attend; please see page 17 for guest ticket pricing.

ABSTRACTS PROGRAM

ORAL POSTER PRESENTATIONS
Friday, May 19 • 10:25–11:25 AM

PRESENTATION METHOD:
All accepted abstracts will be displayed from Thursday evening to Saturday afternoon in the NLA’s newly added Digital Poster Hall, featuring large format, 47-inch flat panel monitors with touchscreen tablets. This will allow abstract presenters to display interactive and dynamic presentations with convenience and savvy. Researchers can now embed video clips, graphics, animations, and 3D models into their poster presentations. Presenters also have the option to split their poster into multiple pages on PowerPoint. The utilization of electronic poster boards supports the NLA’s go-green efforts.

During the designated hours on Saturday, authors will be available for a Q&A about their abstracts in the Poster Hall. In addition, selected abstracts will be identified for live oral presentations during the sessions.

NEW THIS YEAR – DIGITAL POSTER HALL

SANOFI REGENERON YOUNG INVESTIGATOR AWARD
Lead presenters with accepted abstracts who are Young Investigators compete for the Sanofi Regeneron Young Investigator Award. The top three finalists receive a cash prize of $1,000, $750, and $500, respectively, as well as a $1,000 travel grant. The 4th and 5th place finalists receive $1,000 travel grants. The award winners will receive recognition at a special ceremony on Friday, May 19. In addition, the first place winner will present his/her abstract during the Oral Poster Presentations and have their poster printed in the LipidSpin following the meeting.

FOUNDATION OF THE NLA HUNNINGHAKE FH ABSTRACT AWARD*
For the third-straight year, the Foundation of the NLA is proud to present the Foundation of the National Lipid Association Hunninghake FH Abstract Award for the best submitted abstract in familial hypercholesterolemia research. The winner is determined by the Foundation of the NLA Board of Directors and the prize is a $1,500 with an additional $1,000 travel grant. The winner will also present their abstract during the Oral Poster Presentations.

*Supported by AstraZeneca
HONORS & AWARDS CEREMONY

SATURDAY, MAY 20 • 5:30−7:00 PM

The NLA, in cooperation with the certification bodies of the American Board of Clinical Lipidology (ABCL) and the Accreditation Council for Clinical Lipidology (ACCL) will host its annual Honors & Awards Ceremony. The NLA will present the W. Virgil Brown Distinguished Achievement Award, the Honorary Lifetime Member Award, the President’s Service Award, and the Chapter Service Awards, as well as induct the 2016 class of Fellows of the NLA. The ABCL and ACCL will recognize those who successfully passed the ABCL or Clinical Lipid Specialist exams.

STEP CHALLENGE

THURSDAY, MAY 18–SATURDAY, MAY 20

Help us in our mission to promote healthy lifestyles! Join the NLA’s inaugural Step Challenge to compete with your peers to take the most steps during your time in Philadelphia!

1. Check-in at the Step Challenge desk on Thursday, May 18 to get started.
2. Link your personal step-tracker device (smartphone, Fitbit, Jawbone, etc.) to the Step Challenge mobile app. The first 150 registrants will receive a complimentary step-tracker band.
3. The mobile app will immediately start tracking your progress. Gain extra steps by visiting the Exhibit Hall, viewing abstracts in the Digital Poster Hall, or mingling at the Welcome Reception.
4. Periodically stop by the scoreboard to find out who is in the lead. The 1st place winner will receive a complimentary registration to the 2018 Scientific Sessions.

FOUNDATION OF THE NLA EVENT

15th Anniversary Casino Night with the Foundation

SATURDAY, MAY 20 • 7:30–10:00 PM | $170 PER PERSON

Test your luck with the Foundation of the National Lipid Association and celebrate the NLA’s 15th Anniversary in style! Enjoy a night of casino games, dinner, and dancing while doubling-down with fellow attendees. Gather together and reminisce on the past presidents and the growth of the NLA over the previous 15 years. Bring your friends, good luck charms, and dancing shoes!

Separate registration is required for this event. See registration page to purchase tickets. All ticket and chip purchases benefit the Foundation. Cocktail attire is requested.

Opportunities are available to sponsor tables at this event. If you are interested, or would like more information, contact Chealsea Schroeder at cschroeder@lipidfoundation.org.
The NLA’s Lipid Academy provides a comprehensive, in-depth indoctrination to lipid science and is open to all healthcare professionals interested in developing a core competency in the diagnosis and treatment of dyslipidemia. The interactive Lipid Academy course provides health professionals with the knowledge and tools necessary to work effectively in a lipid practice, and will serve as a preparatory course for the annual Scientific Sessions and other advanced lipid training. Additionally, participants earn NLA endorsed lipid education credits that will help to fulfill the CME requirements necessary to be eligible for the Clinical Lipidologist physician certifying examination, offered by the American Board of Clinical Lipidology (ABCL); the Clinical Lipid Specialist (CLS) Certification examination; or the Lipid Competency Certificate (LCC) exam, offered by the Accreditation Council for Clinical Lipidology (ACCL).

The Lipid Academy is offered as a two-day course prior to each scientific meeting conducted by the NLA.

WEDNESDAY, MAY 17
8:30 AM–5:15 PM
THURSDAY, MAY 18
8:00 AM–3:00 PM

$550 MEMBERS | $950 NON-MEMBERS | $0 TRAINEES

Course Faculty

Lori Alexander, MSHS, RD, CCRC, CLS, FNLA
Site Manager
St. Johns Center for Clinical Research
Ponte Vedra, FL

Michael J. Bloch, MD, FVM, FNLA
Associate Professor
Department of Medicine, University of Nevada School of Medicine
Medical Director
Vascular Care, Renown Institute for Health and Vascular Health
Renown Regional Medical Center
Reno, NV

Ann Liebeskind, MD
Founder, Complex Lipids Clinic
Mobile Health Team
Neenah & Wauwatosa, WI

Joseph J. Saseen, PharmD, CLS, FNLA
Professor
Clinical Pharmacy and Family Medicine
University of Colorado Denver
Anschutz Medical Campus
Aurora, CO

James A. Underberg, MD, MS, FNLA
President-Elect, National Lipid Association
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for Prevention of Cardiovascular Disease
Director, Bellevue Hospital Lipid Clinic
New York, NY

*Diplomate, American Board of Clinical Lipidology
Faculty subject to change

This intensive two-day training course offers an in-depth review of the core curriculum in Clinical Lipidology for healthcare professionals who desire to practice at an advanced level within the field. The new case-based, interactive agenda will improve your clinical decision making skills and help prepare you for certification by the American Board of Clinical Lipidology (ABCL) or the Accreditation Council in Clinical Lipidology (ACCL). For those not preparing for certification, the course provides an excellent update and refresher on core concepts in Lipidology. Learn from leading experts, assess your knowledge of lipid science, and advance your personal standard of practice.

WEDNESDAY, MAY 17
8:00 AM–6:00 PM
THURSDAY, MAY 18
7:30 AM–3:30 PM

$750 MEMBERS | $1,250 NON-MEMBERS | $395 TRAINEES

Course Faculty

Harold E. Bays, MD, FNLA
Medical Director/President
Louisville Metabolic and Atherosclerosis Research Center
Louisville, KY

Alan S. Brown, MD, FNLA
Director, Division of Cardiology
Advocate Lutheran General Hospital
Medical Director
Midwest Heart Specialists at Advocate Healthcare
Clinical Associate Professor of Medicine
Loyola University Stritch School of Medicine
Park Ridge, IL

Anne C. Goldberg, MD, FNLA
Professor of Medicine
Washington University School of Medicine
St. Louis, MO

Terry A. Jacobson, MD, FNLA
Professor of Medicine
Director, Office of Health Promotion and Disease Prevention
Emory University
Atlanta, GA

Kevin C. Maki, PhD, CLS, FNLA
Chief Science Officer
Midwest Center for Metabolic & Cardiovascular Research
Chicago, IL

Carl E. Orringer, MD, FNLA
Associate Professor of Medicine
University of Miami School of Medicine
Miami, FL

*Diplomate, American Board of Clinical Lipidology
Faculty subject to change
ANNUAL SCIENTIFIC SESSIONS

TARGET AUDIENCE
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management.

TYPE OF ACTIVITY
Knowledge

LEARNING OBJECTIVES
At the conclusion of this activity, all participants should be able to:

TOWN HALL
• Translate the historical indications and prescribing guidelines of statins
• Discuss how early outcomes trials and usage guidelines of novel therapies influenced current clinical practices in CVD prevention
• Summarize the potential for PCSK9 inhibitor indication expansion
• Analyze the use of omega-3 fatty acids in patient populations wherein outcomes studies have not been conducted
• Identify emerging lipid drug targets that may be important in ASCVD risk reduction
• Utilize specialized treatment strategies for the management of patients with multiple risk factors

SESSION I: GENETICS & GENOMICS IN LIPIDOLGY & CARDIOVASCULAR RISK REDUCTION
• Review the role of genetics in cardiovascular disease risk assessment and management
• Describe the technologies available for genetic screening

ORAL POSTER PRESENTATIONS
• Critically appraise emerging research and its applications to daily clinical practice

SESSION II: FAMILIAL CHYLOMICRONEMIA SYNDROME
• Describe genetic disorders affecting lipoprotein metabolism and their molecular etiology
• Assess the status of new and emerging treatment options for chylomicronemia and triglyceride management

SESSION III: NEW INFORMATION FOR PCSK9 INHIBITION
• Identify the impact that modifications in diet and exercise have on plasma lipoprotein and PCSK9 concentrations in patients with diagnosed coronary artery disease
• Review the evidence that PCSK9 inhibition benefits patients with type 2 diabetes by the reduction of LDL-C levels, non-HDL-C, lipoprotein(a), and total cholesterol

SESSION IV: FAMILIAL HYPERCHOLESTEROLEMIA UPDATE ON NEW THERAPIES
• Evaluate the clinical effects, safety and efficacy data for treatment options for FH patients
• Appraise treatment recommendations and evidence for screening, diagnosing and treating FH in children

SESSION V: TRIAL UPDATES
• Assess the implications of ongoing lipid treatment outcomes trials for the future clinical management of patients with dyslipidemia
• Apply important recent clinical trials research to daily clinical practice

W. VIRGIL BROWN DISTINGUISHED ACHIEVEMENT AWARD & LECTURESHIP
• Outline current patient guidelines for the diagnosis, management and treatment of dyslipidemia

SESSION VI: ROLE OF NON-INVASIVE IMAGING IN RISK STRATIFICATION & TREATMENT OF ASCVD
• Identify the clinical utility of established and emerging cardiovascular imaging modalities
• Use atherosclerosis imaging modalities to guide therapy of hyperlipidemia

SESSION VII: LESS COMMON LIPID DISORDERS
• Identify the mechanisms of disease expression in rare lipid disorders
• Recognize the role of drug therapy in the management of rare lipid disorders

SESSION VIII: UPDATES IN LIPID THERAPEUTICS 2017
• Critically appraise recent clinical trials and apply important research to daily clinical practice
• Demonstrate the practical application of the NLA Annual Summary to the clinical evaluation and management of patients with dyslipidemia

SESSION IX: THE ROLE OF SOCIAL MEDIA IN PRACTICE
• Describe the role of social media in clinical trial recruitment, disease awareness, and patient education

LIPID ACADEMY

TARGET AUDIENCE
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, advance practice registered nurses, registered nurses, nurse practitioners and registered dietitians with an interest in lipid management.

TYPE OF ACTIVITY
Application, Knowledge

LEARNING OBJECTIVES
At the conclusion of this activity, participants should be able to:

• Describe the functions and sources of cholesterol and triglycerides including the role of lipoproteins in atherosclerosis
• Explain the pathogenesis of atherosclerosis
• Identify the role of inflammation in atherogenesis
• Discuss clinical trials including their role in lipid and lipoprotein treatment in cardiovascular prevention
• Review the clinical trials of lipid-altering drug therapies used in cardiovascular disease prevention
• Apply basic principles of statistics to enhance understanding of clinical trials related to lipid management
• Compare and contrast the effectiveness of available risk assessment instruments and markers in predicting CV risk in all population groups
• Identify primary and secondary causes of dyslipidemia
• Recognize the role of drug therapy in the management of dyslipidemia
• Review the mechanism of action, pharmacokinetics, and efficacy of available FDA approved drugs for the management of lipid disorders
• Assess the side effects of lipid-altering drugs to encourage their safe use in cardiovascular disease prevention
• Describe the appropriate use of lipid-altering drugs in special populations
• Describe effective diet and lifestyle strategies for long-term obesity and dyslipidemia management
• Describe the association of specific dietary patterns such as increased sodium and sugar intake, and the increased risk for cardiovascular disease associated morbidity and mortality
• Compose a clinical care plan for reducing risk of CVD in patients with dyslipidemia
• Analyze case studies in lipid management to improve treatment and prevention of cardiovascular disease
• Analyze lipid cases for health professionals seeing patients with complex disorders
• Identify the management of dyslipidemia in special populations based on gender, culture, and disease variables
• Outline current guidelines on the management and treatment of patients with dyslipidemia

Masters in Lipidology

TARGET AUDIENCE
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, advanced practice registered nurses, nurse practitioners and registered dietitians with an interest in lipid management.

TYPE OF ACTIVITY
Application, Knowledge

LEARNING OBJECTIVES
At the conclusion of this activity, participants should be able to:

• Explain lipoprotein metabolism and its role in the pathogenesis of atherosclerosis
• Describe genetic disorders affecting lipoprotein metabolism
• Describe the vascular biology and pathophysiology of atherosclerosis
• Apply basic principles of evidence based medicine to enhance understanding of clinical trial results, methods for cardiovascular risk stratification, and applying new research into practice
• Explain clinical practice guidelines, the different types of evidence used to make clinical guidelines, and the role of clinical judgment in applying guidelines to practice
• Outline current issues and approaches to global cardiovascular risk assessment
• Assess traditional and emerging biomarkers for the prevention and treatment of atherosclerotic cardiovascular disease
• Review the role of subclinical atherosclerosis testing (imaging) in cardiovascular disease risk assessment and management
• Identify the evidence base that supports current dietary recommendations for heart health
• Describe effective diet and lifestyle (exercise, weight management) strategies for the management of dyslipidemia and cardiovascular risk
• Identify how general dietary patterns and specific macronutrients (fats, carbohydrates) affect coronary heart disease and lipids
• Explain how obesity and adiposopathy contribute to the metabolic syndrome and diabetes mellitus
• Identify management strategies for the cardiometabolic risk factors of the metabolic syndrome
• Review the mechanism of action, pharmacokinetics, and efficacy of approved drugs for the management of lipid disorders
• Assess the side effects of lipid-altering drugs to encourage their safe use in cardiovascular disease prevention
• Review clinical trials of lipid-altering drug therapies used in cardiovascular disease prevention
• Describe combination therapies for the management of complex lipid disorders and residual risk
• Manage complex dyslipidemia and dyslipidemia in special populations

REGISTER AT lipid.org/sessions
The National Lipid Association designates this live activity for a maximum of 18.50 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

**PHYSICIAN CREDIT DESIGNATION STATEMENT**

The National Lipid Association designates this continuing education activity for 100 contact hour(s) (10 CEUs) of the Accreditation Council for Pharmacy Education

Session IV – Universal Activity Number 0624-0000-17-006-L01-P (Knowledge)  
The National Lipid Association designates this continuing education activity for 175 contact hour(s) (175 CEUs) of the Accreditation Council for Pharmacy Education

Session V – Universal Activity Number 0624-0000-17-007-L01-P (Knowledge)  
The National Lipid Association designates this continuing education activity for 175 contact hour(s) (175 CEUs) of the Accreditation Council for Pharmacy Education

W. Virgil Brown Lectureship Session - Universal Activity Number 0624-0000-17-012-L01-P (Knowledge)  
The National Lipid Association designates this continuing education activity for 100 contact hour(s) (10 CEUs) of the Accreditation Council for Pharmacy Education

Session VI – Universal Activity Number 0624-0000-17-008-L01-P (Knowledge)  
The National Lipid Association designates this continuing education activity for 175 contact hour(s) (175 CEUs) of the Accreditation Council for Pharmacy Education

Session VII – Universal Activity Number 0624-0000-17-009-L01-P (Knowledge)  
The National Lipid Association designates this continuing education activity for 175 contact hour(s) (175 CEUs) of the Accreditation Council for Pharmacy Education

Session VIII – Universal Activity Number 0624-0000-17-010-L01-P (Knowledge)  
The National Lipid Association designates this continuing education activity for 200 contact hour(s) (20 CEUs) of the Accreditation Council for Pharmacy Education

Session IX – Universal Activity Number 0624-0000-17-011-L01-P (Knowledge)  
The National Lipid Association designates this continuing education activity for 175 contact hour(s) (175 CEUs) of the Accreditation Council for Pharmacy Education

**NURSING**

This educational activity for 18 contact hours is provided by The National Lipid Association.  
The National Lipid Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Town Hall – 2.2 credits; Session I – 11 credits; Oral Posters – 1 credits; Session II – 17 credits; Session III – 1 credits; Session IV – 17 credits; Session V – 17 credits; W. Virgil Brown Lectureship Session 0.6 credits; Session VI – 17 credits; Session VII – 17 credits; Session VIII – 19 credits; Session IX – 17 credits.

**PHYSICIAN ASSISTANTS**

The National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credits™ from organizations accredited by ACCME.

**DIETITIANS**

The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 18 continuing professional education units (CPEUs) for completion of this program/materials. CDR Accredited Provider #NL0002.

**PHARMASTICS**

The National Lipid Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

**TOWN HALL**

This educational activity for 13.5 contact hours is provided by The National Lipid Association.  
The National Lipid Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

**DAY 2 MORNING SESSION** – Universal Activity Number - 0624-0000-17-014-L01-P (Knowledge)  
The National Lipid Association designates this continuing education activity for 4.25 contact hour(s) (425 CEUs) of the Accreditation Council for Pharmacy Education.

**DAY 2 AFTERNOON SESSION** – Universal Activity Number - 0624-0000-17-015-L01-P (Knowledge)  
The National Lipid Association designates this continuing education activity for 13.5 contact hour(s) (1350 CEUs) of the Accreditation Council for Pharmacy Education.
provided by The National Lipid Association. The National Lipid Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Day 1 Morning Session – 3.1 credits; Day 1 Afternoon Session – 4.2 credits; Day 2 Morning Session – 4 credits; Day 2 Afternoon Session – 2.2 credits.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

MASTERS IN LIPIDOLOGY COURSE

The National Lipid Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

The National Lipid Association designates this live activity for a maximum of 16.00 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

PHYSICIAN ASSISTANTS

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

DIETITIANS

The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 16 continuing professional education units (CPEUs) for completion of this program/materials. CDR Accredited Provider #NL0002.

PHARMACISTS

The National Lipid Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

DAY 1 MORNING SESSION – Universal Activity Number - 0624-0000-17-017-L01-P (Knowledge)
The National Lipid Association designates this continuing education activity for 4.00 contact hour(s) (.40 CEUs) of the Accreditation Council for Pharmacy Education.

DAY 1 AFTERNOON SESSION – Universal Activity Number - 0624-0000-17-018-L01-P (Knowledge)
The National Lipid Association designates this continuing education activity for 4.50 contact hour(s) (.450 CEUs) of the Accreditation Council for Pharmacy Education.

DAY 2 MORNING SESSION – Universal Activity Number - 0624-0000-17-019-L01-P (Knowledge)
The National Lipid Association designates this continuing education activity for 5.00 contact hour(s) (.50 CEUs) of the Accreditation Council for Pharmacy Education.

DAY 2 AFTERNOON SESSION – Universal Activity Number - 0624-0000-17-020-L01-P (Application)
The National Lipid Association designates this continuing education activity for 2.25 contact hour(s) (.225 CEUs) of the Accreditation Council for Pharmacy Education.

NURSING

This educational activity for 15.6 contact hours is provided by The National Lipid Association. The National Lipid Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Day 1 Morning Session – 4.0 credits; Day 1 Afternoon Session – 4.5 credits; Day 2 Morning Session – 4.9 credits; Day 2 Afternoon Session – 2.2 credits.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

CRITERIA FOR SUCCESS:

Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at lipid.org/cme.

For Pharmacists: Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

DISCLOSURE STATEMENT:

It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity.

COMMERCIAL SUPPORT:

Full notification of commercial support will be provided in the activity front matter.

Download THE APP*

*Attendees will receive an email when the app is ready to download. Subscribe to our email list at lipid.org/subscribe to receive the email.
Get ENGAGED

Be part of the conversation and get the latest news and announcements from the Scientific Sessions. Follow the NLA on Twitter, Instagram, LinkedIn, and Facebook. Use the hashtag #NLAsessions when posting about the meeting.

NLA MEMBERS SAVE UP TO $505

Not yet a member? Become a member of the National Lipid Association today, and take advantage of the member discounts. Save up to $505 on registration. For only $150, you can enjoy a multitude of member benefits, including discounts on other educational resources. Learn more about the NLA membership by visiting lipid.org/join.

NLA’S TRAINEE TRAVEL GRANT PROGRAM

Are you an in-training practitioner with a focus in lipid management? Learn about the NLA’s Trainee Travel Grant Program! Limited number of grants are available for the NLA Lipid Academy Courses, each including a $500 travel grant and complimentary attendance for Lipid Academy — plus NLA membership for lipid focused trainees is always complimentary. Due to the popularity of this program, please act quickly. For more information, contact Amanda East at aeast@lipid.org. For additional trainee opportunities, visit lipid.org/education/trainees.

Venue & TRAVEL INFO

PHILADELPHIA MARRIOTT DOWNTOWN
1201 Market St.
Philadelphia, PA 19107

MEETING ROOM RATE: $229/night++
ROOM RESERVATION CUT-OFF DATE: April 24, 2017

A sleek style offering many amenities including a cutting-edge fitness center, a heated in-door pool, and great dining options, the Marriott Philadelphia Downtown is a great venue in the perfect location. It is within walking distance to Independence Hall, the Liberty Bell, and the Philadelphia Museum.

For reservations call 1-877-212-5752 and ask for the National Lipid Association room block. Reserve your room early to get a discounted rate.

TRAVEL INFORMATION:
Book your airfare on Delta and receive up to 5% off your flight to Philadelphia. Book your flight on delta.com and enter NMPL3 in the “offer” code box when searching for your flight. Discount applicable for travel to and from Philadelphia between May 13–24, 2017.
Registration

REGISTER ONLINE AT LIPID.ORG/SESSIONS

1

First Name ___________________________ Middle Initial ___________________________ Last Name ___________________________

Mailing Address ___________________________

City ___________________________ State or Province ___________________________ Zip ___________________________ Country ___________________________

Phone ___________________________ Emergency Contact/Phone ___________________________ Cell Phone ___________________________

Email ___________________________

2

Check all that apply: ☐ MD/DO/PhD ☐ RN ☐ NP ☐ PA ☐ RPH ☐ PharmD ☐ RD ☐ Other ___________________________ Specialty ___________________________

Circle fee based on attendee type

<table>
<thead>
<tr>
<th></th>
<th>NLA Member Discount Rate up to 3/31/17</th>
<th>NLA Member Discount Rate after 3/31/17</th>
<th>Non-Member Registration Rate</th>
<th>Trainee Rate*</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCIENTIFIC SESSIONS</td>
<td>$645</td>
<td>$695</td>
<td>$1150</td>
<td>$75</td>
</tr>
<tr>
<td>May 18–21, 2017</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Includes one admission badge to Exhibit Hall for all food functions.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PROFESSIONAL DEVELOPMENT</th>
<th>Masters in Lipidology May 17–18, 2017</th>
<th>Lipid Academy May 17–18, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration Fee Total</td>
<td>$750</td>
<td>$550</td>
</tr>
<tr>
<td></td>
<td>$750</td>
<td>$550</td>
</tr>
<tr>
<td></td>
<td>$1,250</td>
<td>$950</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$395</td>
</tr>
</tbody>
</table>

|                          | $645                                   | $695                                   | $1150                       | $75           |
|                          |                                        |                                        |                             |               |
|                          | $750                                   | $750                                   | $1,250                      | $395          |
|                          |                                        |                                        |                             |               |
|                          | $645                                   | $695                                   | $1150                       | $75           |
|                          |                                        |                                        |                             |               |
|                          | $645                                   | $695                                   | $1150                       | $75           |
|                          |                                        |                                        |                             |               |
|                          | $645                                   | $695                                   | $1150                       | $75           |

3

GUEST FEES & EVENTS

☐ Exhibit Hall Pass – Guest(s) $150 ☐ NLA Foundation Event: 15th Anniversary Casino Night $170

Combined Total Sections 2, 3 & 4 $ _________

4

PAYMENT METHOD

☐ VISA ☐ MC ☐ AMEX ☐ Check

Credit Card # ___________________________ Exp. Date ___________________________

Signature ___________________________ Name on Card ___________________________

5

Guest name(s), if attending meeting:

Membership status:

☐ I am currently a member
☐ My application for membership has been submitted and confirmed
☐ I will apply at lipid.org
☐ Please send me membership information

Registration: Registration and payment must be received no later than April 18, 2017. After this date a name badge cannot be guaranteed.

By registering for the 2017 NLA Scientific Sessions, attendee understands and agrees that attendee’s name, city, and state may be shared with other attendees and exhibitors. By allowing an exhibitor to scan the conference badge, attendee understands, agrees, and consents to the sharing of attendee’s contact information with the company that scanned the conference badge.

Cancellation: Telephone cancellations will not be accepted. A written notice of cancellation must be received no later than April 18, 2017. This includes social events and guest fees. There will be a $100 fee for all cancellations.

Special needs: ___________________________

ADA Compliance: Attendees who need additional reasonable accommodations or who have special needs should contact the NLA at 904-998-0864.

Master’s Course: To purchase the NLA-SAPs please go to lipid.org/education/nlasap

*Trainee Rate: Available for those individuals actively enrolled in a graduate or postgraduate training program for the treatment or investigation of lipid disorders and in pursuit of full credentialing in their specialized area of medical study. A letter from the program director or the school registrar must accompany the application. Fax to 904-998-0855.

Registration Discount Disclaimer: Discount codes cannot be retroactively applied to existing meeting registrations. The meeting discount codes are applicable to new registrants only.

3 EASY WAYS TO REGISTER

Online lipid.org/sessions

Mail National Lipid Association 6816 Southpoint Parkway, Suite 1000 Jacksonville, FL 32216

Fax NLA at 904-998-0865 Fax with credit card number and signature
STAY TUNED for your invitation to attend the Translational Science of the LDL Receptor: an NLA Core Curriculum Intensive Program. This masters-level course is designed to address knowledge and practice gaps in managing residual CVD risk related to elevated levels of LDL-C and to provide lipid specialists with improved proficiency on the complexities of LDL metabolism, functionality, and targets of therapy.

Earn CME/CE Credits

lipid.org/sessions

The course will be offered as a 1.5-day course prior to the start of the NLA’s 2017 Scientific Sessions.

CURRICULUM

- The Discovery of the LDL-Receptor
- Biology and Physiology of the LDL-Receptor
- LDL-Receptor Genetics
- Clinical Considerations Related to LDL-Receptor Dysfunction
- Lp(a) and Interactions with LDL-Receptors
- Mutations Impacting LDL-Receptor Function
- Therapeutic Interventions to Improve LDL-Receptor Function
- Challenging Patient Cases